Resynchronization therapy: implications for pacemaker implantation in Europe.

Panos E Vardas, Emmanuel N Simantirakis
{"title":"Resynchronization therapy: implications for pacemaker implantation in Europe.","authors":"Panos E Vardas,&nbsp;Emmanuel N Simantirakis","doi":"10.1023/a:1023626603839","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac resynchronization has proved a valuable adjunctive therapy in heart failure patients with ventricular conduction disturbances. It improves the patient's clinical status and quality of life, increases functional capacity and causes left ventricular reverse remodeling. The application of this new therapeutic method is expected to affect the pacemaker implantation rate, although the exact degree cannot yet be calculated. One of the main determining factors is the number of patients who are candidates for resynchronization therapy. Although this cannot be estimated precisely, it seems that it does not exceed 10-14% of heart failure patients. Additional factors that will influence the implantation rate, at least during the next few years, are the familiarization of cardiologists with the new implantation technique and follow-up, the availability of cardiac laboratory time and the cost of this new therapy. Although the latter seems high, the financial burden will be minimal when it is taken into consideration that it will lead to a decrease in the number of hospital admissions and a significant reduction in the number of hospitalization days, the greatest determining factors in the current high management cost of heart failure patients. Further to the above, taking the differences between the implantation rates of conventional pacing systems into account in different European countries, the same could be expected of biventricular systems. Thus, although the incidence of heart failure is constantly increasing and conduction disturbances are frequent in such patients, we believe that the implantation rate of biventricular systems in Europe will not exceed an average of 10 per million population, fluctuating according to the country. In conclusion, resynchronization therapy has been established in special subsets of heart failure patients. Due to the epidemiological characteristics of heart failure, the implantation rate is expected to rise. Possible education and/or training issues that appear will be addressed respectively, enabling all suitable patients to enjoy the benefits this new therapeutic technique ensures.</p>","PeriodicalId":80888,"journal":{"name":"Cardiac electrophysiology review","volume":"7 1","pages":"27-9"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/a:1023626603839","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac electrophysiology review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1023/a:1023626603839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Cardiac resynchronization has proved a valuable adjunctive therapy in heart failure patients with ventricular conduction disturbances. It improves the patient's clinical status and quality of life, increases functional capacity and causes left ventricular reverse remodeling. The application of this new therapeutic method is expected to affect the pacemaker implantation rate, although the exact degree cannot yet be calculated. One of the main determining factors is the number of patients who are candidates for resynchronization therapy. Although this cannot be estimated precisely, it seems that it does not exceed 10-14% of heart failure patients. Additional factors that will influence the implantation rate, at least during the next few years, are the familiarization of cardiologists with the new implantation technique and follow-up, the availability of cardiac laboratory time and the cost of this new therapy. Although the latter seems high, the financial burden will be minimal when it is taken into consideration that it will lead to a decrease in the number of hospital admissions and a significant reduction in the number of hospitalization days, the greatest determining factors in the current high management cost of heart failure patients. Further to the above, taking the differences between the implantation rates of conventional pacing systems into account in different European countries, the same could be expected of biventricular systems. Thus, although the incidence of heart failure is constantly increasing and conduction disturbances are frequent in such patients, we believe that the implantation rate of biventricular systems in Europe will not exceed an average of 10 per million population, fluctuating according to the country. In conclusion, resynchronization therapy has been established in special subsets of heart failure patients. Due to the epidemiological characteristics of heart failure, the implantation rate is expected to rise. Possible education and/or training issues that appear will be addressed respectively, enabling all suitable patients to enjoy the benefits this new therapeutic technique ensures.

再同步化治疗:对欧洲起搏器植入的影响。
心脏再同步化已被证明是一种有价值的辅助治疗心力衰竭患者心室传导障碍。它改善了患者的临床状态和生活质量,增加了功能能力,引起左心室反向重构。这种新的治疗方法的应用有望影响心脏起搏器的植入率,尽管确切的程度还不能计算出来。其中一个主要的决定因素是需要再同步治疗的患者数量。虽然不能精确估计,但似乎不超过心力衰竭患者的10-14%。至少在接下来的几年中,影响植入率的其他因素是心脏病专家对新的植入技术和随访的熟悉程度,心脏实验室时间的可用性以及这种新疗法的成本。虽然后者看起来很高,但考虑到它将导致住院人数减少和住院天数显著减少,经济负担将是最小的,这是目前心力衰竭患者高管理成本的最大决定因素。除此之外,考虑到不同欧洲国家传统起搏系统的植入率差异,双心室系统的植入率也会有所不同。因此,尽管心力衰竭的发生率在不断增加,这类患者的传导障碍也很频繁,但我们认为,欧洲双心室系统的植入率不会超过每百万人平均10个,根据国家而波动。总之,再同步化治疗已经在特殊的心衰患者亚群中建立起来。由于心力衰竭的流行病学特点,预计植入率将上升。可能出现的教育和/或培训问题将分别解决,使所有合适的患者都能享受到这种新的治疗技术所带来的好处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信